The largest series of post TAVI coronary occlusion published

Original title: Predictive Factors, Management and Clinical Outcomes of Coronary obstruction Following Transcatheter Aortic Valve Implantation Insight From a Large Multicenter Registry Reference: Henrique B. Ribeiro, et; al. J Am Coll Cardiology 2013;62:1552-62

Percutaneous implantation of the aortic valve is a valid strategy in high-risk surgical patients. One of the possible complications of this procedure is the occlusion of the coronary arteries by displacing calcium during implantation.

In this multicenter registry 6688 patients were included, all received a percutaneous valve implantation, in 44 cases (0.66 %) symptomatic coronary occlusion was observed. Patients with this complication were older, women, higher EuroSCORE log, history of prior biological valve replacement and also more common balloon- expandable valves. By contrast, the history of previous myocardial revascularization surgery was a protective factor. Using CT they had a lower aortic area, smaller diameter at the sinotubular junction, and less distance between the valve and the coronary ostium (

Conclusion:

Occlusion of coronary arteries during implantation of an aortic valve (PCI) is a complication that compromises life, is more common in women, with expandable balloon valves in those who previously received biological valve. The low confinement of the Ostia and the sinuses of Valsalva physiognomies are anatomical factors associated with treatment success and also important to anticipate or prevent the occurrence of this complication.

Comment

Although coronary occlusion is rare, its presence adversely impacts directly on the immediate and short -term developments, in addition to prolonging hospitalization and the cost of the procedure. This complication is related to the anatomy of the valve and can be evaluated by CT. Proper patient selection, implant device and technological improvements of the new valves will decrease this eventuality.

Courtesy Dr Carlos Fava .
Interventional Cardiologist
Favaloro Foundation – Argentina

Dr. Carlos Fava para SOLACI.ORG

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....